Story thread · 2 reports / 2 sources
Gossamer Bio submits NDA for seralutinib in PAH treatment
investing.com · 7h · first report
The coverage
- Gossamer Bio submits NDA for seralutinib for pulmonary arterial hypertension
seekingalpha.com · 5h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.